David H. Henry, MD, on Advances in Lung Cancer, Colorectal Cancer: Expert Perspective
2017 ASCO Annual Meeting
David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 blockade, and epacadostat plus pembrolizumab in lung cancer.
Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital, discusses phase III study findings on lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. (Abstract 4001)
Matthew D. Hellmann, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)
Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)
Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.
Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.